• Successful outcome of platelet transfusion depends on specific antiplatelet therapy in use.
Introduction
Dual antiplatelet therapy with aspirin and a P2Y12 antagonist is standard of care for patients with stable coronary artery disease (CAD) or acute coronary syndrome (ACS) after percutaneous coronary intervention [1] . On-treatment bleeding is relatively modest with the second-generation thienopyridine clopidogrel, and higher with the more potent third-generation oral P2Y12 antagonists prasugrel and ticagrelor [2] [3] [4] . Because bleeding tendency correlates with morbidity and mortality [5] , immediate sustained reversal of platelet inhibition is imperative in acute bleeding, such as intracranial hemorrhage, trauma or surgical interventions such as coronary artery bypass grafting. Donor blood transfusion is the conventional approach to restore platelet function but outcome depends strongly on the pharmacology of the P2Y12 inhibitor present [6] . Active metabolites of clopidogrel and prasugrel bind irreversibly to the P2Y12 receptor and are relatively short lived, so transfused platelets are less likely to be inhibited by residual free antagonist. Ticagrelor, by contrast, is direct acting and binds P2Y12 reversibly, requiring steady plasma concentrations to be effective. However, these properties permit inhibition of transfused platelets, as highlighted by two recent case reports [7, 8] . Both patients receiving ticagrelor as loading or maintenance dosing for ACS suffered intracranial hemorrhage and died despite platelet transfusion (of up to 17 units of platelets), which increased platelet count but failed to restore platelet function. Some years ago, we presented preliminary ex vivo observations that platelet transfusion may not adequately counteract ticagrelor [9, 10] and several studies, including the APTITUDE trial, have since confirmed this finding [11] [12] [13] [14] .
To date, the impact of stable maintenance medication with ticagrelor, in comparison with both clopidogrel and prasugrel, has not been examined in a standardized study. We therefore used our initial ex vivo mixing approach, mimicking transfusion, to systematically study the reactivity of fresh donor platelets in the presence of platelets or plasma from patients on stable medication with prasugrel, clopidogrel or ticagrelor. HLA2/HLA28 haplotyping let us distinguish net and individual responses of patient and donor platelets in mixtures. We found that donor platelet reactivity is indeed dramatically reduced by plasma and platelets from ticagrelor-treated patients compared with clopidogrel or prasugrel, implying that platelet transfusion may not achieve immediate and sustained reversal of inhibition by ticagrelor.
Methods
The study was conducted with the approval of the institutional ethics committee and in accordance with the Declaration of Helsinki.
Patient population
Patients with cardiovascular disease receiving standard care including a P2Y12 antagonist were recruited at the Department of Cardiology and Angiology, University Hospital Muenster, Germany. Inclusion and exclusion criteria were aligned with the Summary of Product Characteristics (SPC) for each agent. Patients (both sexes, 18-65 years, > 60 kg) on stable maintenance medication (> 1 month continuously) with prasugrel (10 mg day À1 , n = 20), clopidogrel (75 mg day À1 , n = 20) or ticagrelor (90 mg twice daily, n = 20) were included. Patients were well matched with respect to stable CAD or ACS. Patients' characteristics, history and current medications are shown in Table S1 . Patients with acute health events during the last month, previous stroke, transient ischemic attack or active bleeding, such as peptic ulcer, were excluded. Citrate-anticoagulated blood (20 mL, 9:1 blood: trisodium citrate 0.108 mol L À1 ) was obtained with informed consent during a routine visit.
Na€ ıve donors
Healthy blood donors (both sexes, 18-65 years, > 60 kg) not receiving any platelet modifying therapies in the preceding 14 days were recruited at the Institute for Transfusion Medicine and Transplantation Immunology, University Hospital Muenster, Germany, and provided informed consent for sampling of 20 mL citrate-anticoagulated blood.
Sample preparation
In strict adherence to a standardized protocol, patient blood was obtained exactly 4 h [14, 15] after the last intake of P2Y12 antagonist and after exactly 30 min of rest, and processed immediately after collection. Plateletrich and platelet-poor plasma (PRP, PPP) and gel-filtered platelets (GFP) were prepared as described and mixed directly after preparation [16, 17] .
Control measures
Potential donors were assessed at a time-point prior to collection to exclude platelet function defects, confirmed by fibrinogen-FITC (fluorescein isothiocyanate) binding and CD62P surface expression [18, 19] . Measurement of ADP-stimulated CD62P externalization was performed in the presence of the thromboxane-mimetic U46619 (0.5 lM) [19] .
HLA2/HLA28 typing
Patient and donor platelets were typed for HLA2 and HLA28 as described [20] and additionally by flow cytometry. This enabled appropriate matching of donor/patient pairs and assessment of individual platelet populations within mixtures. Donors were typed some weeks prior to study and patients upon collection. Differentiation of patient and donor platelets by flow cytometry utilized a labelled anti-HLA A2 antibody (One Lambda Inc., Kittridge, CA, USA) cross-reacting with A28 [21] ( Figure S1 ). Mixing HLA2-positive and negative PRP samples from healthy donors was confirmed not to affect ADP-induced platelet activation ( Figure S2A ). To identify residual P2Y12 inhibitor activity in plasma, the influence of increasing amounts of patient plasma on donor GFP was evaluated after 15 min incubation. Functional readouts were flow cytometry assessment of fibrinogen binding and externalization of CD62P in response to increasing concentrations of ADP (Sigma-Aldrich, Taufkirchen, Germany), as previously described [18, 19] . The impact of increasing concentrations of donor plasma on GFP responsiveness to ADP is depicted in Figure S2B .
Statistical comparison
Data show mean or median as indicated AE standard deviation of n = 20 per group. Statistical analysis was performed by analyses of variance and multiple comparison procedures as appropriate. P < 0.05 was accepted as significant.
Results
Platelet-rich plasma (PRP) from patients on ticagrelor but not thienopyridines inhibits donor platelet function ADP-stimulated fibrinogen binding and CD62P externalization were determined in donor and patient PRP mixtures. Increasing proportions of PRP from patients on stable medication with either clopidogrel (Fig. 1 ) or prasugrel ( Fig. 2 ) only modestly attenuated net platelet responses, with no significant impact on individual patient or donor platelet function. Even at the lowest concentration (10%) of PRP from patients receiving ticagrelor, significant suppression of net and donor platelet fibrinogen binding and CD62P externalization was found (Fig. 3) ; patient platelet responses were not further affected.
Responsiveness of donor platelets to the two highest concentrations of ADP examined (0.5 and 1 lM) was also significantly suppressed by PRP from patients on ticagrelor compared with clopidogrel or prasugrel, across the entire range of ratios ( Figure S3 ). The individual data points of the 20 donor:patient pairs showing retained donor platelet responsiveness to 1 lM ADP in a 1:9 mix of donor:patient PRP, confirmed significant suppression through medication with ticagrelor compared with the two thienopyridines (Fig. 4) . Modest impairment by prasugrel-PRP compared with clopidogrel was significant only for fibrinogen binding ( Fig. 4A ) but not CD62P expression (Fig. 4B ).
Donor platelet function is inhibited more strongly by plasma from patients on ticagrelor than from those on clopidogrel or prasugrel ADP-stimulated fibrinogen binding and CD62P expression by GFP were determined in the presence of increasing concentrations of plasma (PPP) from patients receiving P2Y12 antagonists. Plasma from clopidogreltreated patients reduced donor platelet fibrinogen binding at concentrations ≥ 20% (Fig. 5A ) without influencing CD62P expression (Fig. 5B) . Plasma from prasugrel patients similarly attenuated donor GFP fibrinogen binding, from the lowest concentration (10%) examined (Fig. 5C ), without affecting CD62P externalization (Fig. 5D ). The degree of inhibition of donor GFP reactivity by increasing concentrations of clopidogrel or prasugrel patient plasma reflected the inhibition seen in donor GFP upon addition of increasing concentrations of donor plasma (control study, n = 3, Supplementary Figure 2B ). Plasma from ticagrelor patients elicited more marked suppression of ADP-stimulated fibrinogen binding to donor GFP (Fig. 5E ) and significantly suppressed CD62P expression at all concentrations examined (Fig. 5E ). Individual data points of the 20 donor:patient pairs showing retained donor platelet responsiveness to 1 lM ADP in a 1:9 ( Fig. 6A ) or 1:1 mix of donor:patient PRP (Fig. 6B) , confirmed significant suppression of donor GFP fibrinogen binding in the ticagrelor group compared with the two thienopyridines. The same impact was seen in terms of CD62P expression (Fig. 6C, D) .
Gel-filtered platelets (GFP) from patients on ticagrelor but not clopidogrel or prasugrel inhibit donor platelet function
Responsiveness of donor GFP to ADP (1 lM), both fibrinogen binding (Fig. 7A ) and CD62P externalization (Fig. 7B) , was significantly suppressed in the presence of 50% (i.e. 1:1 mix) with GFP from patients receiving ticagrelor, compared with clopidogrel or prasugrel. Responsiveness of ticagrelor-treated patient platelets upon mixing with donor platelets (1:9 and 1:1 mix of donor:patient GFP), however, showed no recovery, either for fibrinogen binding (Fig. 7C ) or CD62P expression (Fig. 7D ).
Discussion
We demonstrate that, in contrast to clopidogrel and prasugrel, stable medication with ticagrelor suppresses donor platelet function in an ex vivo mixing study. This inhibition may be attributable to ticagrelor and/or its active metabolite(s) present in patient plasma, and/or to dissociation of reversibly bound ticagrelor/active metabolite present on patient platelets, as summarized in Table S2 . The doses used (clopidogrel 75 mg day À1 , prasugrel 10 mg day À1 , ticagrelor 90 mg twice daily) are consistent with everyday clinical therapy and the observations made here thus provide a valid reflection of the consequences to be expected in a transfusion setting. Donor platelet transfusion was mimicked ex vivo by mixing fresh donor platelets with platelets from patients on stable (> 1 month) medication with clopidogrel, prasugrel or ticagrelor, obtained exactly 4 h after the previous maintenance dose. This time-point reflects a realistic minimum interval between dosing and necessity for transfusion, and was also examined in the recent APTI-TUDE study [14] , albeit that study examined the impact of loading doses of P2Y12 antagonists. In mixed donor/ patient PRP preparations, net (all platelet) and donor platelet functions were suppressed by increasing proportions of PRP from ticagrelor-treated patients. Even the lowest concentration (10%) of patient PRP led to a significant reduction in ADP-stimulated fibrinogen binding and CD62P externalization, compared with PRP from patients on clopidogrel or prasugrel. Retained donor platelet responsiveness to ADP (1 lM) in the presence of 10% patient PRP (i.e. 1:9 mix donor:patient) remained around 100% (= responsiveness in pure donor PRP) when patients received clopidogrel. Responsiveness was slightly reduced by PRP from patients on prasugrel, but the strongest suppression (> 50%) was consistently seen with PRP from ticagrelor patients.
Blood transfusion is the conventional strategy to immediately restore platelet function and hemostatic potential during acute bleeding or surgery. Transfusion of a single apheresis platelet concentrate (equivalent to six to eight random donor platelet concentrates) will raise the platelet count of a 70-kg patient by~30 000 lL À1 (i.e. approximately 10% of the total platelet count of a normal adult) [22] . Our finding that even 10% of patient PRP markedly inhibited donor platelet function may explain the inability of platelet transfusions to restore platelet function after ticagrelor intake in the clinical setting. Potentially, even mass transfusion of donor platelets may not counteract ticagrelor. In a similar study combining PRP from patients on prasugrel with increasing proportions of control PRP, platelet reactivity was restored in 90% of samples when the ratio of non-inhibited to inhibited platelets was at least 3:2. By contrast, platelets from ticagrelor-treated patients failed to regain functionality regardless of how many naive platelets were added. Taken together, partial platelet transfusion may be of little help in ticagrelor-treated patients requiring urgent platelet function recovery, as demonstrated by the case studies outlined earlier [7, 8] . Such cases may in fact require complete exchange transfusion. To assess if residual antagonist and/or active metabolite (s) in patient plasma caused the inhibitory effect, GFP from healthy donors were studied with increasing amounts of patient plasma. Again, maintenance therapy with ticagrelor led to strong suppression of donor platelet responsiveness in comparison with clopidogrel or prasugrel. Plasma from patients receiving the latter two substances inhibited donor GFP to a similar extent to plasma from healthy donors. For ticagrelor, by contrast, even the lowest concentration of patient plasma (10%) led to significant reductions in ADP-stimulated fibrinogen binding and CD62P expression. At the highest concentration studied (50%), fibrinogen binding was nearly completely suppressed. Plasma from clopidogrel-or prasugrel-treated patients also reduced fibrinogen binding to donor GFP at both 10% and 50% concentrations, so at the time of blood collection (4 h after last intake), sufficient amounts of all three P2Y12 antagonists/active metabolites remain in plasma to impair donor platelet responses. This concept is consistent with the plasma half-lives of the active metabolites of clopidogrel and prasugrel [23] . The inhibitory impact of plasma from patients on thienopyridines was much more modest than with ticagrelor, and CD62P expression was largely unaffected. Competitive binding of unlabeled fibrinogen present in PPP is unlikely to account for the impairment of FITClabelled fibrinogen binding, given our control experiment (Supplementary Figure 2B) and the fact that PPP from the three patient groups behaved differently, with ticagrelor consistently showing the strongest impact. Ticagrelor and its active metabolite bind P2Y12 reversibly, thus continuously high plasma concentrations are required for effective platelet inhibition. In contrast to the irreversibly bound thienopyridines, therefore, dissociation of ticagrelor and its active metabolite could conceivably inhibit transfused donor platelets. As P2Y12 internalizes upon agonist binding and recycles to the plasma membrane following agonist removal [24] , ticagrelor may potentially be internalized with the receptor and released again to the plasma, whereas clopidogrel and prasugrel would remain bound to P2Y12.
We tested if ticagrelor released from its binding on patient platelets interferes with donor platelet function by mixing GFP from donors and patients. ADP responsiveness was reduced by approximately 50% when patients received ticagrelor, whereas GFP from patients on clopidogrel or prasugrel did not reduce donor platelet responsiveness. This supports the hypothesis that reversibly bound ticagrelor and/or its active metabolite dissociate and/or recycle from patient platelets sufficiently to impair the function of non-inhibited donor platelets, without detectably improving ticagrelor-treated patient platelet function. Presumably at 4 h, the overwhelming majority of patient platelet P2Y12 receptors are inhibited, so that the subset of receptors freed upon addition of donor platelets was not enough for a net functional recovery.
Our findings provide a mechanistic explanation for the failure of transfusion to adequately restore platelet function in ticagrelor-treated patients, as highlighted in two recent case reports [7, 8] , and confirm and extend similar observations by others [11, 13, 14] . These preceding studies, however, examined healthy donor samples spiked with ticagrelor [13] , or platelets from patients receiving loading doses of P2Y12 inhibitors [14] , or a combined patient pool that received either loading or maintenance doses of ticagrelor or prasugrel 6-24 h prior to blood sampling [11] . We here provide the first head-to-head comparison of stable maintenance dosing with all three P2Y12 antagonists, rather than examining loading doses or spiked platelet, and assayed 20 patients per group in strict adherence to a standardized protocol designed to minimize variations arising from inadvertent pre-activation of platelets. Besides fibrinogen binding, we examined CD62P (P-selectin) expression, the 'reference standard' marker for ex vivo assessment of platelet activation [25] . Although ADP is a relatively weak agonist for CD62P externalization, robust responses are achieved with addition of a second stimulus such as thrombin or thromboxane A2 [19] .
In conclusion, we show that the reversible mode of binding of ticagrelor and/or its active metabolite to P2Y12 receptors, and the necessity of its continued presence in plasma, limit the ability of donor platelets to restore platelet function. Accordingly, patients on stable medication with clopidogrel or prasugrel are more likely to benefit from platelet transfusion. Specific antidotes for ticagrelor to enable effective recovery of platelet function on demand are required; MEDI2452, currently in development [26] , is one such candidate. 
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